Abstract | PURPOSE:
MP470 is a multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret that is being evaluated as an anticancer agent. The plasma and cerebrospinal fluid (CSF) pharmacokinetics of MP470 were studied in a non-human primate model that is highly predictive of CSF penetration in humans. METHODS: Oral MP470, 300 mg, was administered to four non-human primates. Serial samples of blood were collected from four animals and CSF samples from three animals for pharmacokinetic studies. Plasma and CSF concentrations were measured using an LC-MS/MS assay. Both model-independent and model-dependent methods were used to analyze the pharmacokinetic data. RESULTS: Following a one-time oral dose of 300 mg, the MP470 plasma area under the curve (AUC) was 1,690 ± 821 nM h (mean ± SD). The half-life of MP470 in the plasma was 11.0 ± 3.4 h. There was no measurable MP470 in the CSF. CONCLUSIONS: Although CSF penetration is minimal, MP470 has demonstrated potent activity against cancer cell lines in vitro and in vivo, and further clinical investigation is warranted.
|
Authors | P A Baxter, P A Thompson, L M McGuffey, B W Gibson, R C Dauser, J G Nuchtern, C Shi, R Inloes, G Choy, S Redkar, S M Blaney |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 67
Issue 4
Pg. 809-12
(Apr 2011)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 20563581
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Thiourea
- amuvatinib
|
Topics |
- Administration, Oral
- Animals
- Antineoplastic Agents
(cerebrospinal fluid, pharmacokinetics)
- Area Under Curve
- Chromatography, Liquid
- Half-Life
- Macaca mulatta
- Male
- Models, Biological
- Piperazines
- Protein Kinase Inhibitors
(cerebrospinal fluid, pharmacokinetics)
- Pyrimidines
(cerebrospinal fluid, pharmacokinetics)
- Tandem Mass Spectrometry
- Thiourea
|